profit from every $100 of sales.
$0$100
Cytek Biosciences
$5.89+1.03% today
+22.5% in 1 year
1-year low $3.361-year high $6.30
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Cytek Biosciences sold, what it kept, and what it did with the cash.
Sales went from $164 million in 2022 to $201 million in 2025, with -$66.5 million of profit last year.
SalesProfit
Cytek Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Cytek Biosciences | No profit yet | ||
 Boston Scientific | 22.0× · Fair price | ||
 Koninklijke Philips | 30.0× · Fair price | ||
 Steris | 31.9× · Expensive | ||
 Zimmer Biomet Holdings | 29.1× · Fair price |
AI analysis
An AI analyst reads Cytek Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 164 | 193 | 200 | 201 | |
| 101 | 109 | 111 | 104 | |
| -2 | -28 | -21 | -40 | |
| 9 | -4 | -10 | -17 | |
| 3 | -12 | -6 | -67 | |
| 0.02 | -0.09 | -0.05 | -0.52 | |
| 61.6% | 56.7% | 55.4% | 51.8% | |
| -1.1% | -14.4% | -10.2% | -20.0% | |
| 1.6% | -6.3% | -3.0% | -33.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 519 | 494 | 500 | 462 |
| Cash | 297 | 167 | 99 | 91 |
| Total debt | 18 | 14 | 17 | 24 |
| Total liabilities | 94 | 101 | 104 | 120 |
| 425 | 393 | 396 | 342 | |
| 139 | 131 | 131 | 128 | |
| 0.7% | -2.6% | -3.9% | -6.3% | |
| 0.6% | -3.1% | -1.5% | -19.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -12 | 5 | 25 | -5 | |
| 10 | 5 | 4 | 4 | |
| -22 | 0 | 22 | -9 | |
| Dividends paid | – | – | – | – |
| 0 | 44 | 22 | 15 | |
| 17 | 22 | 27 | 25 |
Valuation
- –
- –
- –
- 1.6×
- 3.8×
- –
- –
- -1.2%
- -8.6%
- 0.0%
Profitability
- 51.8%
- -20.0%
- -33.0%
- -11.5%
- -11.4%
- -4.3%
- -20.8%
- -16.5%
- -11.9%
- 17.8%
Growth
- +7.1%
- –
- −140.1%
- –
- −1.1%
Financial health
- -3.9×
- 0.11
- 8.1%
- -23.2×
- 4.69
- 4.07
- 0.45
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 948
Bottom 12%of 871
Bottom 35%of 868
Bottom 34%of 985
What analysts expect
- Average price target
- $6.00
- Range
- $6.00 – $6.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.12 | -0.08 | −50.0% |
| Feb 26, 2026 | -0.01 | -0.02 | +50.0% |
| Nov 5, 2025 | -0.01 | 0.01 | −200.0% |
| Aug 6, 2025 | 0.01 | -0.02 | +150.0% |
| May 8, 2025 | -0.09 | -0.04 | −125.0% |
| Feb 27, 2025 | 0.07 | 0.05 | +40.0% |
| Nov 5, 2024 | 0.01 | 0.00 | +166.7% |
| Aug 6, 2024 | -0.08 | -0.03 | −166.7% |
News
Cytek outlines $208M-$211M 2026 revenue range while postponing business unit rollout to 2027Seeking Alpha · Nov 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
31No pass
Benjamin Graham
58No pass
Philip Fisher
35No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
35No pass
Terry Smith
28No pass
Questions about Cytek Biosciences
Is Cytek Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Cytek Biosciences AI analysis
What does Cytek Biosciences do?
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It is in Medical - Devices.
Does Cytek Biosciences pay a dividend?
No. Cytek Biosciences does not pay a dividend at the moment; in 2025 it returned $15.1 million to shareholders by buying back its own shares.
Is Cytek Biosciences stock halal?
Questionable. Cytek Biosciences sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Cytek Biosciences stock done over the past year?
Up 22.5% over the past twelve months, to $5.89. It traded between $3.36 and $6.30 and is 6.5% below its high.
Who are Cytek Biosciences's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with Cytek Biosciences's.
Prices: daily closes to Nov 9, 2026. Fundamentals: company reports via invest-like data.